跳至主要内容
临床试验/ISRCTN59915743
ISRCTN59915743已完成不适用

Improvements in muscle recovery and delayed onset muscle soreness (DOMS) reduction after eccentric exercise with the BounceBack™ product: a randomised, double-blind, two-way crossover, placebo-controlled, pilot study

Mannatech, Inc (USA)0 个研究点目标入组 10 人开始时间: 2008年10月9日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Both males and females, age >=18 and <=45 at screening
  • 2. Body mass index (BMI) >18 kg/m^2 and <=30 kg/m^2 at screening
  • 3. Recreationally active but non-resistance trained for the preceding 3 months
  • 4. Agree to dietary modifications for the day prior to each visit
  • 5. Subject agrees to all study visits
  • 6. Must agree to use appropriate birth control methods during the active study

排除标准

  • 1. Non-compliance during the screening phase of the study
  • 2. Weight loss of >10 pounds in the last 6 months
  • 3. Pregnant or lactating
  • 4. Currently attempting to become pregnant
  • 5. Use of medications or supplements promoting weight gain (steroids, high-protein supplements)
  • 6. Daily use of acid blocking medication. Must agree to withhold acid blocking medication while on study (Includes all prescription and over the counter acid blockers including PPIs, H2RAs, and calcium carbonate [Tums]).
  • 7. Cigarette smoking
  • 8. Abnormal physical examination
  • 9. Subjects unable to understand or follow the study protocol
  • 10. Subjects participating or participated in another clinical trial during the 1 month prior to screening
  • 11. Subjects with active eating disorder including anorexia nervosa, bulimia, restrained eating, and/or obsessive compulsive eating disorders (Subjects will be screened with a standardised eating disorder questionnaire)
  • 12. Subjects with known sensitivities to the ingredients in the product
  • 13. Subjects with untreated significant depression or other psychiatric disease noted during the initial screening. Subjects with stable depression who are receiving medication and/or therapy may be included.
  • 14. Subjects with active coronary artery disease, congestive heart failure, stroke, arrhythmia, or uncontrolled hypertension
  • 15. Any liver, gallbladder or renal disease
  • 16. Subjects with a history of seizure
  • 17. Subjects with any cancer in the last 5 years (except skin cancer)
  • 18. Subjects on anticoagulation therapy
  • 19. Subjects with known alcohol abuse or recreational drug abuse
  • 20. Subjects with chronic malabsorption
  • 21. Subjects with a history of diverticulosis or diverticulitis
  • 22. Subjects with inflammatory bowel disease (ulcerative colitis or Crohn's disease)
  • 23. Subjects with a history of intestinal obstruction or those prone to intestinal obstruction
  • 24. Subjects with short bowel syndrome
  • 25. Subjects with a history of any surgery on their gastro-intestinal system
  • 26. Subjects with a history of perforation of the stomach or intestines
  • 27. Subjects with a history of pancreatitis, pancreatic insufficiency, pancreatic psuedocyst, carcinoma of the pancreas
  • 28. Type I or type II diabetes
  • 29. Subjects with any other endocrinologic disorders (including Cushing's syndrome and/or hypothyroidism)
  • 30. Subjects with a history of lactic acidosis
  • 31. Subjects with a history of symptomatic hypoglycemia
  • 32. Subjects with brain and/or spinal cord injury
  • 33. Subjects who have had diarrhoea in the month prior to the screening visit

研究者

发起方
Mannatech, Inc (USA)

相似试验